Peapod Bio teams up with Enamine to supercharge drug discovery
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated